GLP-1 medications transform obesity treatment approach

GLP-1 receptor agonists, such as semaglutide and tirzepatide, have significantly altered the medical approach to treating obesity by reducing appetite and increasing satiety. While these medications offer substantial weight loss benefits and can improve associated comorbidities, medical professionals emphasize that they are not cosmetic products but treatments for a complex disease involving genetics, hormones, and metabolic factors.

Experts warn against using these injections based solely on peer recommendations or purchasing them from unauthorized sources. Effective treatment requires professional medical supervision, including assessments of weight, blood pressure, and medical history, alongside lifestyle changes such as diet and exercise. Recent research and clinical discussions also highlight the importance of monitoring side effects, including potential impacts on mental health and energy levels.